We are pleased to announce that a recently published scientific communication involving researchers at the Pfizer Institute of Pharmaceutical Materials Science and CCDC has appeared as a CrystEngComm hot-article. The article summarises exciting results assessing the potential of the Mercury Solid Form Suite’s hydrogen bond propensity tool in screening potential co-crystal formers, and is available to view free of charge for 4 weeks from 20th March.
The published study describes the co-crystal screening of the anti-malarial drug pyrimethamine with various pharmaceutically acceptable adducts. Co-crystals offer completely new physical properties compared to a pure active ingredient and are viewed as a rich source of novel solid forms in the pursuit of a stable candidate for drug or agrochemical product development. Co-crystallising pairs of actives with different or complementary pharmacological effects is also an elegant potential route to multi-drug therapy. Developing methods to better suggest successful co-crystallisation experiments is, therefore, of great interest.
